Cargando…
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
The development of a single immuno-metabolic adjuvant capable of modulating, in the appropriate direction and intensity, the complex antagonistic and symbiotic interplays between tumor cells, immune cells, and the gut microbiota may appear pharmacologically implausible. Metformin might help solve th...
Autores principales: | Verdura, Sara, Cuyàs, Elisabet, Martin-Castillo, Begoña, Menendez, Javier A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791450/ https://www.ncbi.nlm.nih.gov/pubmed/31646077 http://dx.doi.org/10.1080/2162402X.2019.1633235 |
Ejemplares similares
-
Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
por: Cuyàs, Elisabet, et al.
Publicado: (2021) -
Circulating levels of MOTS-c in patients with breast cancer treated with metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2022) -
Metformin and breast cancer: an opportunity for pharmacogenetics
por: Cuyàs, Elisabet, et al.
Publicado: (2022) -
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012)